A welcome addition to support our ongoing product development. SpectraCure receives research contribution from the EU

SpectraCure has been awarded with funds from the EU which strengthens the research within the company’s technology, to treat prostate cancer with SpectraCure’s IDOSE dose platform and focal PDT treatment (PDT). The funding enables the employment of a young researcher for four years.

The funding is part of an Innovative Training Network where SpectraCure participates and is awarded through the EU cooperation for research support program, Horizon 2020, and covers the employment of a young researcher (so-called Early Stage Researcher) for four years. The network consists of universities and companies in the EU countries with the theme of the use of laser technology and photonics in medical research.

– The employment of the Early Stage Researcher that is being funded by the EU is a welcoming addition to our already intensive development of IDOSE technology for prostate cancer treatment, and eventually other types of cancer e. g. breast cancer. In addition, it is a confirmation that our research is of high class. This type of grant is awarded in strong competition and is prestigious, says SpectraCure’s CTO Johannes Swartling. This type of grant is awarded in strong competition and is prestigious, says SpectraCure’s CTO Johannes Swartling. says SpectraCure’s CTO Johannes Swartling.

The process of recruiting a researcher will begin immediately. The researcher will be enrolled as a doctoral student at Lund University, but most of the work will be performed at SpectraCure. The purpose is also for an exchange between the universities and the other companies within the network. Privacy and IP rights are governed by an agreement between the parties before the project starts.

For further information, contact:
Masoud Khayyami, CEO SpectraCure. E-mail: mk@spectracure.com

Johannes Swartling, CTO SpectraCure. Phone: +46 (0) 40-16 20 70, e-mail: jsw@spectracure.com.

Certified Adviser is G&W Fondkommission, e-mail: ca@gwkapital.se, phone: +46-(8)-503 000 50.

www.spectracure.com

 

SpectraCure was founded in 2003 as a spin off from Lund University departments for medical laser applications and physics. The company focuses on cancer treatments using medical systems with laser light sources and reactive drugs, which is referred to as “Interstitial Photodynamic Therapy”, PDT, a treatment methodology suitable for internal solid tumours of various kind, e.g. prostate and abdominal salivary glands, but also other indications such as cancer tumours in the head and neck region.